arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

TENAX THERAPEUTICS, INC.

TENX
$1.62 ▼ -0.19 (-10.22%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
70 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

TENAX THERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $82.4M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -13.1% ↘
FCF / Share $-0.28 ↘
Trailing P/E —
Price / Book 0.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

70-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-15.72M
↓ -51.0% —
FCF / Share Free cash flow per share
$-0.28
↓ -35.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑
16
Cash Quality ↑
48

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 70 quarters